Pharming Group Past Earnings Performance
Past criteria checks 0/6
Pharming Group's earnings have been declining at an average annual rate of -56.7%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 6.5% per year.
Key information
-56.7%
Earnings growth rate
-57.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 6.5% |
| Return on equity | -7.9% |
| Net Margin | -6.2% |
| Last Earnings Update | 30 Sep 2024 |
Revenue & Expenses Breakdown
How Pharming Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 286 | -18 | 195 | 72 |
| 30 Jun 24 | 278 | -13 | 187 | 72 |
| 31 Mar 24 | 258 | -11 | 184 | 72 |
| 31 Dec 23 | 245 | -11 | 175 | 69 |
| 30 Sep 23 | 219 | -22 | 160 | 68 |
| 30 Jun 23 | 206 | -16 | 157 | 60 |
| 31 Mar 23 | 202 | -2 | 140 | 53 |
| 31 Dec 22 | 206 | 14 | 127 | 53 |
| 30 Sep 22 | 204 | 30 | 110 | 69 |
| 30 Jun 22 | 202 | 21 | 100 | 70 |
| 31 Mar 22 | 202 | 11 | 94 | 70 |
| 31 Dec 21 | 199 | 16 | 91 | 65 |
| 30 Sep 21 | 200 | 22 | 88 | 48 |
| 30 Jun 21 | 200 | 31 | 83 | 44 |
| 31 Mar 21 | 202 | 37 | 79 | 41 |
| 31 Dec 20 | 212 | 38 | 76 | 39 |
| 30 Sep 20 | 212 | 44 | 75 | 33 |
| 30 Jun 20 | 202 | 46 | 70 | 32 |
| 31 Mar 20 | 202 | 42 | 69 | 33 |
| 01 Jan 20 | 189 | 41 | 66 | 33 |
| 30 Sep 19 | 175 | 38 | 58 | 38 |
| 30 Jun 19 | 175 | 34 | 60 | 36 |
| 31 Mar 19 | 158 | 29 | 55 | 32 |
| 31 Dec 18 | 155 | 29 | 54 | 33 |
| 30 Sep 18 | 152 | -29 | 56 | 27 |
| 30 Jun 18 | 138 | -44 | 53 | 25 |
| 31 Mar 18 | 128 | -80 | 53 | 24 |
| 31 Dec 17 | 108 | -91 | 45 | 22 |
| 30 Sep 17 | 76 | -53 | 32 | 21 |
| 30 Jun 17 | 47 | -47 | 21 | 20 |
| 31 Mar 17 | 31 | -21 | 13 | 17 |
| 31 Dec 16 | 17 | -18 | 8 | 16 |
| 30 Sep 16 | 12 | -16 | 6 | 17 |
| 30 Jun 16 | 12 | -15 | 6 | 16 |
| 31 Mar 16 | 13 | -14 | 6 | 17 |
| 31 Dec 15 | 12 | -11 | 5 | 15 |
| 30 Sep 15 | 29 | 8 | 6 | 14 |
| 30 Jun 15 | 27 | 9 | 5 | 14 |
| 31 Mar 15 | 23 | 10 | 4 | 13 |
| 31 Dec 14 | 26 | -7 | 4 | 14 |
| 30 Sep 14 | 6 | -29 | 3 | 15 |
| 30 Jun 14 | 6 | -35 | 3 | 14 |
| 31 Mar 14 | 11 | -35 | 3 | 15 |
| 31 Dec 13 | 9 | -21 | 3 | 14 |
Quality Earnings: PHAR is currently unprofitable.
Growing Profit Margin: PHAR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PHAR is unprofitable, and losses have increased over the past 5 years at a rate of 56.7% per year.
Accelerating Growth: Unable to compare PHAR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PHAR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: PHAR has a negative Return on Equity (-7.89%), as it is currently unprofitable.